Expert Opinion on Therapeutic Patents最新文献_第3页

CBL-B - An upcoming immune-oncology target. 关于治疗专利的专家意见 - 手稿编号 EOTP-2024-ST-0024 已在线提交。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2025-01-01 Epub Date: 2024-11-25 DOI: 10.1080/13543776.2024.2412567

Riccardo Fusco, Zeinab Saedi, Imma Capriello, Andriy Lubskyy, Alexander Dömling

{"title":"CBL-B - An upcoming immune-oncology target.","authors":"Riccardo Fusco, Zeinab Saedi, Imma Capriello, Andriy Lubskyy, Alexander Dömling","doi":"10.1080/13543776.2024.2412567","DOIUrl":"10.1080/13543776.2024.2412567","url":null,"abstract":"Introduction: The E3 ubiquitin ligase Cbl-b is a novel target in immune-oncology, with critical roles in regulating T-cell activation and signaling pathways. By facilitating the ubiquitination and degradation of key signaling proteins, Cbl-b modulates immune responses, maintaining immune homeostasis and preventing unwarranted T-cell proliferation. The therapeutic potential of Cbl-b as a cancer immunotherapy target is underscored by its contribution to an immunosuppressive tumor microenvironment, with efforts currently underway to develop small-molecule inhibitors.Areas covered: We reviewed the small molecules, and antibody-drug conjugates targeting Cbl-b from 2018 to 2024. The patents were gathered through publicly available databases and analyzed with in-house developed cheminformatic workflow, described within the manuscript.Expert opinion: Targeting Cbl-b presents a promising approach in immuno-oncology, offering a novel pathway to potentiate the immune system's ability to combat cancer beyond PDL1/PD1 inhibition. The development and clinical advancement of Cbl-b inhibitors, as evidenced by the ongoing trials, mark a significant step toward harnessing this target for therapeutic benefits. Overall, the strategic inhibition of Cbl-b holds substantial promise for improving cancer immunotherapy outcomes, heralding a new era in the fight against cancer.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"47-64"},"PeriodicalIF":5.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A patent review of UNC-51-like kinase 1/2 inhibitors (2019-present). UNC-51 样激酶 1/2抑制剂专利回顾（2019 年至今）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2025-01-01 Epub Date: 2024-11-04 DOI: 10.1080/13543776.2024.2423010

Zhiqi Zhang, Dejuan Sun, Yueying Yang, Samir Y Abbas, Hua Li, Lixia Chen

{"title":"A patent review of UNC-51-like kinase 1/2 inhibitors (2019-present).","authors":"Zhiqi Zhang, Dejuan Sun, Yueying Yang, Samir Y Abbas, Hua Li, Lixia Chen","doi":"10.1080/13543776.2024.2423010","DOIUrl":"10.1080/13543776.2024.2423010","url":null,"abstract":"Introduction: UNC-51-like kinase 1/2 (ULK1/2) are serine/threonine kinases that play a crucial role in autophagy activation and maintaining cellular homeostasis. Given their broad physiological relevance, ULK1/2 are candidate targets for treating various diseases. In recent years, ULK1/2 inhibitors have made significant progress, and the highly potent ULK1/2 inhibitors have entered clinical trials.Area covered: This review aims to provide an updated analysis of patents describing ULK1/2 inhibitors and their potential therapeutic applications that were disclosed between 2019 and 2024.Expert opinion: Due to their crucial role in various diseases, the invention of small-molecule drugs targeting ULK1/2 is particularly important, especially in cancer treatment. Despite the great success of ULK1/2 inhibitors development, ULK1/2 inhibitors are ATP competitive inhibitors of aminopyrimidines currently, and most ULK1/2 inhibitors are still in the preclinical research stage, with only DCC-3116 entered clinical research. Therefore, developing highly selective ULK1/2 inhibitors with low side effects and high bioavailability remains a challenging and promising research direction.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"7-16"},"PeriodicalIF":5.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

WD repeat domain 5 (WDR5) inhibitors: a patent review (2016-present). WD重复结构域5 （WDR5）抑制剂：专利审查（2016年至今）

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2025-01-01 Epub Date: 2024-12-22 DOI: 10.1080/13543776.2024.2441658

Jesse A Coker, Shaun R Stauffer

{"title":"WD repeat domain 5 (WDR5) inhibitors: a patent review (2016-present).","authors":"Jesse A Coker, Shaun R Stauffer","doi":"10.1080/13543776.2024.2441658","DOIUrl":"10.1080/13543776.2024.2441658","url":null,"abstract":"Introduction: WDR5 is an epigenetic scaffolding protein that has attracted significant interest as an anti-cancer drug target, especially in MLL-rearranged leukemias. The most druggable 'WIN-site' on WDR5, which tethers WDR5 to chromatin, has been successfully targeted with multiple classes of exquisitely potent small-molecule protein-protein interaction inhibitors. Earlier progress has also been made on the development of WDR5 degraders and inhibitors at the 'WBM-site' on the opposite face of WDR5.Areas covered: Based on an international survey of the patent literature using SciFinder from 2016-2024, herein we provide a comprehensive account of the chemical matter targeting WDR5, with a particular focus on proprietary compounds that are underreported in the existing academic literature. Our survey illuminates challenges for the field to overcome: a broad lack of chemical diversity, confusion about the molecular mechanism of WIN-site inhibitors, a paucity of brain-penetrant scaffolds despite emerging evidence of activity in brain cancers, sparse pharmacokinetic, metabolic, and disposition characterization, and the absence of safety or efficacy data in humans.Expert opinion: It is our opinion that the best-in-class WIN-site inhibitors (from the imidazole class) merit advancement into clinical testing, likely against leukemia, which should provide much-needed clarity about the exciting but unproven potential of WDR5 as a next-generation therapeutic target.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"31-45"},"PeriodicalIF":5.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Menin-MLL protein-protein interaction inhibitors: a patent review (2021-present). Menin-mll 蛋白-蛋白相互作用抑制剂：专利回顾（2021 年至今）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2025-01-01 Epub Date: 2024-11-03 DOI: 10.1080/13543776.2024.2422380

Fang Wang, Zhe Yang, Yujie Wu, Huanrong Bai, Minhang Xin

{"title":"Menin-MLL protein-protein interaction inhibitors: a patent review (2021-present).","authors":"Fang Wang, Zhe Yang, Yujie Wu, Huanrong Bai, Minhang Xin","doi":"10.1080/13543776.2024.2422380","DOIUrl":"10.1080/13543776.2024.2422380","url":null,"abstract":"Introduction: Acute leukemia harboring rearrangement of the Mixed lineage leukemia (MLL) and/or mutation of the nucleophosmin is a type of poorly prognostic and highly malignant leukemia which is extremely difficult to treat. Blocking the protein-protein interaction between Menin and MLL is a strategic approach for treating leukemias, as a new direction for drug discovery. Many biotech and pharmaceutical companies made great efforts to this drug development field, and a large number of small molecular Menin-MLL PPI inhibitors were reported during the recent three years.Areas covered: This review is to mainly summarize the Menin-MLL PPI inhibitors reported in the recent three years' patents.Expert opinion: Although the past 12 years have witnessed the progress of the Menin-MLL PPI inhibitors in the treatment of acute leukemia, especially for leukemia harboring rearranged KMT2A and/or mutated NPM1, recent studies showed Menin-MLL PPI inhibitors suffered from new issues such as toxicity, acquired resistance, and homogenization. Therefore, new drug discovery strategies should be considered in advance. The expert opinion was proposed from several aspects, such as developing diverse chemical structures, discovering covalent inhibitors, designing small molecular PROTACs, and targeting the amino acids mutations for next-generation inhibitors.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"65-78"},"PeriodicalIF":5.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US20240132615. 用于多发性骨髓瘤的三特异性抗 CD3/BCMA/CD38 抗体：US20240132615 的专利评估。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2025-01-01 Epub Date: 2024-10-29 DOI: 10.1080/13543776.2024.2423018

Cindy Bandala, Donaciano Flores-Robles, Pavel Sierra-Martínez, Alejandro Millán-Vega, Eunice Ruíz González, Martin Perez-Santos

引用次数: 0

"A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018-present)". “花生四烯酸脂氧合酶（LOX）抑制剂治疗神经退行性疾病的专利审查（2018年至今）”。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-12-27 DOI: 10.1080/13543776.2024.2447067

Danai-Eleni Vergini, Dimitra Hadjipavlou-Litina

{"title":"\"A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018-present)\".","authors":"Danai-Eleni Vergini, Dimitra Hadjipavlou-Litina","doi":"10.1080/13543776.2024.2447067","DOIUrl":"10.1080/13543776.2024.2447067","url":null,"abstract":"Introduction: Neuroinflammation is correlated to neurodegenerative diseases like Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Huntington Disease (HD), and Parkinson's disease (PD). A lot of recent research and patents are focused on the design and synthesis of arachidonic acid lipoxygenase (ALOX) inhibitors for the treatment of neurodegenerative diseases.Areas covered: The survey covers natural products, synthesis, hybrids, and assessments of biological effects in biological studies as ALOX inhibitors. A survey of patent publications from 2018 to present, taken from Google Scholar, Espanet, Web of Science, Drugbank, Scopus, or PubMed is analyzed.Expert opinion: The authors suggest that (i) numerous areas of biology-pharmacology need to be considered: selectivity, in vivo studies, toxicity, bioavailability, and drug-likeness, the mechanism of action in different animals and humans, evaluation of more efficient and selective biological tests; (ii) synthetic method outbalance in the discovery and production of ALOX inhibitors with greater selectivity. Several ALOX inhibitors show promising results for the treatment of neurological disorders. Their clinical evaluation will be critical to assess therapeutic utility. The compounds for which the mechanism of action and their bioavailability are well defined can be used as lead compounds for the treatment of neurodegenerative diseases.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1-14"},"PeriodicalIF":5.4,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142880980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A patent review of mitogen-activated protein kinase-interacting kinases (MNKs) modulators (2019-present). 丝裂原活化蛋白激酶相互作用激酶（MNKs）调节剂专利回顾（2019年至今）

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-12-26 DOI: 10.1080/13543776.2024.2446225

Qiang Li, Xiang Chen, Mingzhi Su, Yue-Wei Guo, Xin Jin

{"title":"A patent review of mitogen-activated protein kinase-interacting kinases (MNKs) modulators (2019-present).","authors":"Qiang Li, Xiang Chen, Mingzhi Su, Yue-Wei Guo, Xin Jin","doi":"10.1080/13543776.2024.2446225","DOIUrl":"10.1080/13543776.2024.2446225","url":null,"abstract":"Introduction: The mitogen-activated protein kinase interacting kinases (MNKs) modulate protein translation through the phosphorylation of eukaryotic initiation factor 4E (eIF4E) at serine 209, which is crucial for tumorigenesis but dispensable for normal development. MNKs are implicated in various pathological processes, including inflammation, obesity, cancer, etc. Thus, MNKs are considered as potential drug targets and the development of potent and selective MNK inhibitors is a current research focus.Areas covered: This review covers inhibitors of MNKs reported in patents published in the online databases of the World Intellectual Property Organization and European Patent Office from 2019 to 2024. This review provides a landscape of available inhibitors, including their chemical structures, activity, and stage of development.Expert opinion: In recent years, highly potent and selective inhibitors have been discovered and many of them show promising results in several preclinical cancer models. The majority of small-molecule inhibitors developed recently, similarly to the structure of eFT508 and ETC-206. Also, some new skeletons were disclosed and showed novel mechanisms, including non-traditional ATP competition and induced protein degradation by proteolysis targeting chimeras. Ongoing preclinical research and clinical trials will provide us more information on these new compounds and MNKs novel functions beyond cancer.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1-14"},"PeriodicalIF":5.4,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patent landscape of small molecule inhibitors of METTL3 (2020-present). METTL3小分子抑制剂专利格局（2020年至今）

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-12-26 DOI: 10.1080/13543776.2024.2447056

Zhixing Wu, Alexis R Smith, Zhijian Qian, Guangrong Zheng

{"title":"Patent landscape of small molecule inhibitors of METTL3 (2020-present).","authors":"Zhixing Wu, Alexis R Smith, Zhijian Qian, Guangrong Zheng","doi":"10.1080/13543776.2024.2447056","DOIUrl":"https://doi.org/10.1080/13543776.2024.2447056","url":null,"abstract":"Introduction: Methyltransferase-like protein 3 (METTL3), in complex with METTL14, is the key 'writer' protein for RNA m6A methylation, accounting for almost all mRNA m6A modifications. Recent studies reveal that METTL3 is implicated in the development and progression of various types of cancers. Targeting METTL3 with small molecule inhibitors represents a promising therapeutic strategy for cancer.Areas covered: This review provides an overview of the patent literature covering METTL3 inhibitors. A literature search was conducted in SciFinder by using 'METTL3 inhibitor' as a keyword and was refined by narrowing the criteria to patents.Expert opinion: Efforts to develop METTL3/METTL14 inhibitors have led to the advancement of the drug candidate STC-15 to clinical trials. Preclinical studies of STC-15 show promise in inhibiting tumor growth via direct anti-tumor effects and anti-cancer immune responses. The clinical trial outcomes of STC-15 will shape future METTL3/METTL14 inhibitor development. However, critical questions remain. The role of METTL3/METTL14 in m6A RNA methylation is essential for cellular activity, raising concerns about the potential adverse effects of targeting this complex. Furthermore, depending on the context, METTL3/METTL14 can function as a tumor suppressor. This underscores the need for a deeper understanding of the molecular mechanisms by which RNA modifications regulate cancer.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1-16"},"PeriodicalIF":5.4,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An updated patent review of SOS1 inhibitors (2022-present). SOS1 抑制剂最新专利回顾（2022 年至今）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-12-01 Epub Date: 2024-10-25 DOI: 10.1080/13543776.2024.2419825

Guizhen Zhou, Chuan Zhou, Xinyi Ma, Jiahang Xu, Zehui Zhou, Tianfeng Xu, Mingyue Zheng, Sulin Zhang

{"title":"An updated patent review of SOS1 inhibitors (2022-present).","authors":"Guizhen Zhou, Chuan Zhou, Xinyi Ma, Jiahang Xu, Zehui Zhou, Tianfeng Xu, Mingyue Zheng, Sulin Zhang","doi":"10.1080/13543776.2024.2419825","DOIUrl":"10.1080/13543776.2024.2419825","url":null,"abstract":"Introduction: SOS1 is a crucial guanine nucleotide exchange factor for KRAS. It facilitates the transition of KRAS from inactive GDP-bound state to active GTP-bound state. The activation of KRAS triggers downstream signaling pathways, promoting tumor initiation and progression. Inhibiting SOS1 to prevent KRAS activation is an effective strategy for treating tumors driven by KRAS.Areas covered: This review identified patents claiming to be SOS1 inhibitors or SOS1-KRAS interaction modulators published between January 2022 and June 2024 using Cortellis Drug Discovery Intelligence. A total of 15 patent applications from 5 different applicants were assessed.Expert opinions: In KRAS-driven tumors, inhibiting SOS1 significantly affect cell proliferation and migration by modulating the RAS/MAPK and PI3K/AKT/mTOR signaling pathways. Since 2022, numerous patents for SOS1 inhibitors have been published. The majority of SOS1 inhibitors are currently in the preclinical phase of development, with only a few progressing to clinical trials. However, these inhibitors face significant challenges in clinical studies, including limited efficacy of monotherapies, safety concerns, and the necessity to enhance PK properties. Despite their excellent in vitro performance, SOS1 inhibitors must address issues related to safety, pharmacokinetics, and pharmacodynamics in clinical applications.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1199-1213"},"PeriodicalIF":5.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mycobacterium tuberculosis inhibitors: an updated patent review (2021-present). 结核分枝杆菌抑制剂：最新专利回顾（2021 年至今）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-12-01 Epub Date: 2024-11-18 DOI: 10.1080/13543776.2024.2419826

Salvucci Benedetta, Francesco Vallini, Michela Guida, Chiara Tammaro, Mariangela Biava, Giovanna Poce

{"title":"Mycobacterium tuberculosis inhibitors: an updated patent review (2021-present).","authors":"Salvucci Benedetta, Francesco Vallini, Michela Guida, Chiara Tammaro, Mariangela Biava, Giovanna Poce","doi":"10.1080/13543776.2024.2419826","DOIUrl":"10.1080/13543776.2024.2419826","url":null,"abstract":"Introduction: Tuberculosis (TB) remains a major global health issue, causing around 10 million new cases and 1.3 million deaths in 2022. The challenge is compounded by multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains, and co-infection with HIV.Areas covered: The present review examines significant patent literature on TB chemotherapeutics from September 2021 to the present using the following databases, reaxys, google patent and espacenet. Only patents reporting compounds with a minimum inhibitory concentration (MIC) on whole Mycobacterium tuberculosis cells of ≤5 µM were selected for review.Expert opinion: The fight against TB is advancing with the development of promising new compounds due to the challenge of drug-resistant strains. Notable among those reviewed in this paper are the benzothiazinones, showing high efficacy against both drug-sensitive and resistant TB strains. Additionally, Q203 analogues, demonstrate strong antitubercular activity, good microsomal stability, and favorable safety profiles. Finally, LysRS inhibitors also show significant promise in vivo models. These advancements underscore the importance of novel targets and innovative strategies in developing effective, resistance-resistant TB treatments.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1215-1230"},"PeriodicalIF":5.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0